Study guide

14.1 USP <800> & NIOSH Hazardous Drug Standards

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

14.1 USP <800> & NIOSH Hazardous Drug Standards

Key Takeaways Explain This Topic AI

United States Pharmacopeia (USP) General Chapter <800> establishes legally enforceable containment standards for the entire lifecycle of hazardous drugs (HDs)—receipt, storage, compounding, dispensing, administration, transport, decontamination, and waste management—to safeguard healthcare personnel, patients, and the environment.

The National Institute for Occupational Safety and Health (NIOSH) categorizes hazardous drugs into three distinct groups based on six toxicity criteria: Group 1 (Antineoplastic drugs), Group 2 (Non-antineoplastic hazardous drugs meeting toxicity criteria), and Group 3 (Non-antineoplastic drugs with primarily adverse reproductive/developmental risks).

Healthcare entities must maintain a facility-specific hazardous drug list reviewed at least every 12 months, overseen by a formally designated, qualified individual ('Designated Person') responsible for standard operating procedures, continuous quality assurance, and personnel competency.

An Assessment of Risk (AoR) may be performed to establish alternative containment strategies only for intact, unmanipulated dosage forms (e.g., counting intact oral tablets/capsules) and Group 2/3 agents; active pharmaceutical ingredients (APIs) of ANY hazardous drug and antineoplastic agents requiring compounding manipulation CANNOT be exempted and strictly require full USP <800> engineering controls.

Mandatory personnel training and documented competency verification must occur prior to handling hazardous drugs and be repeated at least annually, paired with a comprehensive medical surveillance program to track exposure, baseline health metrics, and reproductive risk acknowledgments.

Last updated: August 2026

14.1 USP <800> & NIOSH Hazardous Drug Standards

Occupational exposure to antineoplastic and other hazardous medications represents one of the most critical health and safety challenges in oncology practice. Decades of epidemiological and biological monitoring studies have demonstrated that healthcare personnel—including pharmacists, pharmacy technicians, oncology nurses, shipping and receiving staff, and environmental services workers—routinely face occupational risks from airborne vapors, aerosols, dermal absorption, and surface contamination. Uncontrolled exposure has been causally linked to acute toxicities (skin rashes, hair loss, nausea), chronic organ damage, genotoxic alterations (chromosomal aberrations, sister chromatid exchanges), adverse reproductive outcomes (spontaneous abortions, congenital malformations, fetal loss, infertility), and secondary malignancies (leukemias and lymphomas).

To establish comprehensive, legally enforceable containment standards, the United States Pharmacopeial Convention developed USP General Chapter <800> "Hazardous Drugs—Handling in Healthcare Settings." Board-Certified Oncology Pharmacists (BCOP) must thoroughly understand the regulatory scope of USP <800>, the National Institute for Occupational Safety and Health (NIOSH) categorization framework, facility-specific list maintenance, the Assessment of Risk (AoR) algorithm, and mandatory medical surveillance requirements.

1. Regulatory Framework & Interplay of USP Compounding Chapters

USP <800> operates in direct synergy with other foundational compounding and handling chapters within the United States Pharmacopeia. While earlier chapters focus primarily on product quality and patient safety, USP <800> is uniquely engineered to protect occupational personnel, the patient, and the healthcare environment . +---------------------------------------------------------------------------------------------------+

  • | INTERPLAY OF USP COMPOUNDING & HANDLING CHAPTERS |
  • | |
  • | [USP <795>] Non-Sterile Compounding |
  • | - Focus: Product sterility is NOT required; ensures chemical potency, purity, beyond-use dates |
  • | - HD Overlap: When compounding non-sterile HDs, USP <800> containment rules apply |
  • | |
  • | [USP <797>] Sterile Compounding |
  • | - Focus: Product sterility, microbial contamination prevention, environmental ISO cleanliness |
  • | - HD Overlap: When compounding sterile HDs, BOTH USP <797> (sterility) and USP <800> |
  • | (containment) standards must be simultaneously satisfied |
  • | |
  • | [USP <800>] Hazardous Drugs — Handling in Healthcare Settings |
  • | - Focus: OCCUPATIONAL & ENVIRONMENTAL PROTECTION across the entire medication lifecycle |
  • | - Enforceability: Applies to ALL healthcare settings and personnel handling HDs (receipt, |
  • | storage, compounding, transport, dispensing, administration, deactivation, waste disposal) |
  • | |
  • | [USP <825>] Radiopharmaceuticals |
  • | - Focus: Handling, compounding, and dispensing of radioactive materials and radiolabeled HDs |
  • +---------------------------------------------------------------------------------------------------+
  • Regulatory Enforceability & Jurisdiction

State Boards of Pharmacy: Directly enforce USP standards through state pharmacy practice acts, administrative codes, and routine facility inspections.

Food and Drug Administration (FDA): Enforces compliance under Sections 503A (traditional compounding pharmacies) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Occupational Safety and Health Administration (OSHA): Enforces safe workplace environments under the General Duty Clause (Section 5(a)(1)) and the Hazard Communication Standard (29 CFR 1910.1200), utilizing USP <800> and NIOSH alerts as established industry consensus standards.

Accreditation Organizations: The Joint Commission (TJC), DNV GL Healthcare, and ACHC inspect healthcare facilities for strict compliance with USP <800> policies and procedures.

2. NIOSH Hazardous Drug Definition & Toxicity Criteria

The National Institute for Occupational Safety and Health (NIOSH), a research agency within the Centers for Disease Control and Prevention (CDC), establishes the scientific criteria used to define hazardous drugs. Under the NIOSH definition, a drug is classified as hazardous if, in animal or human studies, it exhibits one or more of the following six toxicity characteristics : +---------------------------------------------------------------------------------------------------+

  • | NIOSH SIX HAZARDOUS DRUG TOXICITY CRITERIA |
  • | |
  • | 1. CARCINOGENICITY: |
  • | Ability to induce cancer or increase the incidence of benign/malignant neoplasms. |
  • | Examples: Alkylating agents (Cyclophosphamide, Melphalan, Busulfan), Etoposide. |
  • | |
  • | 2. TERATOGENICITY OR DEVELOPMENTAL TOXICITY: |
  • | Ability to cause structural malformations, fetal growth retardation, or developmental arrest.|
  • | Examples: Thalidomide, Lenalidomide, Pomalidomide, Methotrexate, Retinoids. |
  • | |
  • | 3. REPRODUCTIVE TOXICITY: |
  • | Impairment of fertility, gonadal dysfunction, menstrual irregularities, or embryo lethality. |
  • | Examples: Ganciclovir, Ribavirin, Tamoxifen, Finasteride, Dutasteride. |
  • | |
  • | 4. ORGAN TOXICITY AT LOW DOSES: |
  • | Significant organ toxicity observed at doses <=10 mg/day or <=1 mg/kg/day in animal models. |
  • | Examples: Cyclosporine, Tacrolimus, Mycophenolate mofetil, Azathioprine. |
  • | |
  • | 5. GENOTOXICITY: |
  • | Ability to damage DNA structures, induce mutations, or cause chromosomal aberrations. |
  • | Examples: Cisplatin, Carboplatin, Carmustine, Fluorouracil, Doxorubicin. |
  • | |
  • | 6. STRUCTURE AND TOXICITY MIMICRY: |
  • | New chemical entities possessing molecular structures and toxicity profiles that closely |
  • | resemble existing hazardous agents (e.g., novel kinase inhibitors, modified antimetabolites).|
  • +---------------------------------------------------------------------------------------------------+
  • 3. NIOSH Hazardous Drug Categorization Groups

NIOSH maintains and periodically updates a comprehensive list of hazardous drugs used in healthcare settings, stratifying agents into three operational groups :

NIOSH Group Category Description Defining Pharmacologic Characteristics Representative Drug Examples

Group 1 Antineoplastic Drugs Chemotherapeutic agents, cytotoxic antineoplastics, antibody-drug conjugates (ADCs), targeted antineoplastic kinase inhibitors, and hormonal oncolytics used primarily to treat malignant neoplasms. Doxorubicin, Cisplatin, Cyclophosphamide, Methotrexate, Paclitaxel, Fluorouracil, Ibrutinib, Osimertinib, Brentuximab vedotin, Enfortumab vedotin, Lenalidomide.

Group 2 Non-Antineoplastic Hazardous Drugs Drugs that meet one or more NIOSH toxicity criteria (carcinogenicity, organ toxicity at low doses, genotoxicity) but are NOT used primarily to treat cancer. Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate mofetil, Spironolactone, Carbamazepine, Divalproex/Valproic acid, Topiramate, Zidovudine.

Group 3 Non-Antineoplastic Drugs with Reproductive/Developmental Risks Medications that pose hazards exclusively or primarily to personnel who are actively pregnant, attempting to conceive, or breastfeeding; do not exhibit generalized organ toxicity at low doses. Finasteride, Dutasteride, Ribavirin, Ganciclovir, Valganciclovir, Letrozole/Anastrozole (when used for non-oncology indications like ovulation induction), Fluconazole (high dose), Oxytocin.

  • 4. Facility-Specific HD List & The Assessment of Risk (AoR)
  • Entity-Specific Hazardous Drug List Requirements

Under USP <800>, each healthcare institution must establish, maintain, and document its own facility-specific hazardous drug list . This list must include:

All items on the current NIOSH list that the facility receives, stocks, compounds, dispenses, or administers.

Any newly FDA-approved drugs or investigational drugs entering the formulary that meet NIOSH hazardous criteria.

Annual Mandatory Review: The list must be reviewed and documented at least once every 12 months (or whenever a new agent or dosage form is introduced) by the Designated Person.

The "Designated Person" Role

USP <800> mandates that every entity handling hazardous drugs must assign one or more qualified individuals as the Designated Person . The Designated Person is formally responsible for:

Developing, approving, implementing, and enforcing standard operating procedures (SOPs).

Ensuring continuous compliance with USP <800>, state, and federal containment mandates.

Overseeing environmental monitoring, facility engineering maintenance, and certification.

Supervising personnel training, initial and annual competency evaluations, and medical surveillance.

Assessment of Risk (AoR) Decision Algorithm

USP <800> allows healthcare entities to perform a documented Assessment of Risk (AoR) to evaluate whether certain hazardous drug dosage forms may be handled with alternative containment strategies rather than full engineering controls. +---------------------------------------------------------------------------------------------------+

  • | USP <800> ASSESSMENT OF RISK (AoR) DECISION ALGORITHM |
  • | |
  • | IS THE DRUG AN ACTIVE PHARMACEUTICAL INGREDIENT (API) OF ANY HAZARDOUS DRUG? |
  • | | |
  • | +---> [YES] ================================> MUST FOLLOW FULL USP <800> CONTAINMENT! |
  • | | (C-PEC, C-SEC, Storage, Full PPE) |
  • | +---> [NO] (NO AoR EXEMPTION ALLOWED!) |
  • | | |
  • | v |
  • | IS IT AN ANTINEOPLASTIC DRUG REQUIRING MANIPULATION? |
  • | (e.g., Compounding IV solutions, crushing tablets, opening capsules, reconstituting powders) |
  • | | |
  • | +---> [YES] ================================> MUST FOLLOW FULL USP <800> CONTAINMENT! |
  • | | (C-PEC, C-SEC, Storage, Full PPE) |
  • | +---> [NO] (NO AoR EXEMPTION ALLOWED!) |
  • | | |
  • | v |
  • | IS IT AN INTACT FINISHED DOSAGE FORM OR GROUP 2 / GROUP 3 HAZARDOUS DRUG? |
  • | (e.g., Counting intact unit-dose oral tablets, administering pre-packaged oral liquid/capsule) |
  • | | |
  • | +---> [YES] --------------------------------> ELIGIBLE FOR ASSESSMENT OF RISK (AoR) |
  • | - Evaluate drug type, dosage form, packaging|
  • | - Define alternative containment strategies |
  • | - Document and review AoR every 12 months! |
  • +---------------------------------------------------------------------------------------------------+
  • Alternative Containment Strategies Under AoR

When an AoR is performed for eligible intact dosage forms (e.g., counting intact tablets of spironolactone, methotrexate, or capecitabine), the facility may establish alternative SOPs:

Dedicated Equipment: Utilizing dedicated counting trays, spatulas, and automated dispensing cells marked exclusively for hazardous drugs, thoroughly cleaned with deactivating agents after each use.

Automated Counting Restrictions: Prohibiting the use of high-speed automated pill counters/counting robots that create airborne dust or particulate friction.

Packaging & Enclosure: Dispensing medications in unit-dose packaging or sealed plastic pouches to eliminate subsequent handling manipulation by bedside nurses.

Personal Protective Equipment: Requiring a single pair of chemotherapy-tested gloves (ASTM D6978) during counting and packaging operations.

5. Personnel Training, Competencies & Medical Surveillance +---------------------------------------------------------------------------------------------------+

  • | USP <800> PERSONNEL TRAINING & COMPETENCY TIMELINE |
  • | |
  • | [INITIAL ONBOARDING] |
  • | - Prior to independently handling any hazardous drug |
  • | - Didactic instruction on HD list, risks, SDS interpretation, SOPs, and engineering controls |
  • | - Practical demonstration: Donning/doffing PPE, aseptic manipulation, CSTD use, spill response |
  • | - Documented signature acknowledging reproductive and occupational health risks |
  • | | |
  • | v |
  • | [RECURRENT ANNUAL COMPETENCY] |
  • | - Documented reassessment at least once every 12 months |
  • | - Gloved fingertip testing & media-fill simulation (if performing sterile HD compounding) |
  • | | |
  • | v |
  • | [TRIGGER-BASED RE-TRAINING] |
  • | - Introduction of a new hazardous agent, novel equipment (C-PEC/CSTD), or updated SOP |
  • | - Following an accidental spill, occupational exposure incident, or environmental failure |
  • +---------------------------------------------------------------------------------------------------+
  • Occupational Medical Surveillance Program

USP <800> recommends and professional guidelines mandate a structured medical surveillance program to monitor personnel who handle hazardous drugs on a regular basis. The program serves as a secondary line of defense to identify early biological effects or system failures:

Baseline Health Assessment: Comprehensive occupational history, medical/reproductive history, physical examination, and baseline laboratory panels (Complete Blood Count [CBC] with differential, comprehensive metabolic panel [CMP] for hepatic and renal indices, and baseline urinalysis).

Ongoing Health Surveillance: Periodic health evaluations, tracking of acute exposure symptoms (dizziness, nausea, skin rashes, mucosal irritation), and recording of reproductive outcomes.

Post-Exposure & Incident Protocol: Immediate clinical evaluation, decontamination, lab testing, root-cause investigation, and documentation following acute spills, needle-sticks, or splash injuries.

Exit Examination: Documentation of overall health status and cumulative occupational exposure history upon termination of employment or reassignment away from hazardous handling areas.